Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs. Am J Physiol Heart Circ Physiol 2019 Jul 01;317(1):H164-H167

Date

06/08/2019

Pubmed ID

31172808

Pubmed Central ID

PMC6692734

DOI

10.1152/ajpheart.00277.2019

Scopus ID

2-s2.0-85069238135 (requires institutional sign-in at Scopus site)   23 Citations

Abstract

Cardio-oncology has emerged as an exciting new field at the intersection of cardiology and oncology. While improved oncology treatment efficacy has increased survival rates in cancer patients, the long-term cardiovascular consequences of this life-saving treatment have become more clinically relevant. Both traditional and newer (targeted) cancer therapies can have cardiovascular and metabolic sequelae, resulting in heart failure, coronary artery disease, myocarditis, pericardial disease, hypertension, and vascular and metabolic perturbations (Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375: 1457-1467, 2016). Both acute and chronic cardiovascular toxicities have proven challenging for clinicians and patients, significantly contributing to morbidity and mortality. Although chronic cardiovascular disease affects a growing number of cancer survivors (~17 million in the United States in 2019), cardiovascular toxicities associated with cancer and cancer therapies are poorly understood mechanistically. To balance potential damage to the cardiovascular system with effective and efficient cancer treatment, novel strategies are sorely needed. This perspective focuses on an assembly of articles that discuss novel means of counteracting adverse cardiovascular events in response to anticancer therapy. In light of new clinical syndromes in cardiology due to cancer therapies, we hope to highlight promising research opportunities offered by cardio-oncology (Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ. Cardio-oncology: how new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation 132: 2248-2258, 2015.).

Author List

Beyer AM, Bonini MG, Moslehi J

Author

Andreas M. Beyer PhD Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Animals
Anthracyclines
Antibiotics, Antineoplastic
Cardiotoxicity
Cardiovascular System
Heart Diseases
Humans
Protective Agents